Dow Jones
31.447,27 -53,41 (-0,17%) Nasdaq
11.539,77 -67,85 (-0,58%) Nikkei 225
26.871,27 +379,30 (+1,43%) EUR/USD
1,0585 +0,0027 (+0,25%) BTC-EUR
19.680,80 -505,43 (-2,50%) CMC Crypto 200
454,33 -7,47 (-1,62%)
Global Blood Therapeutics, Inc. (0IVZ.L)
| Chiusura precedente | 31,08 |
| Aperto | 30,27 |
| Denaro | 0,00 x 0 |
| Lettera | 0,00 x 0 |
| Min-Max giorno | 30,16 - 30,27 |
| Intervallo di 52 settimane | 30,16 - 30,27 |
| Volume | |
| Media Volume | N/D |
| Capitalizzazione | 1,957B |
| Beta (5 anni mensile) | 1,11 |
| Rapporto PE (ttm) | N/D |
| EPS (ttm) | -4,86 |
| Prossima data utili | 01 ago 2022 - 05 ago 2022 |
| Rendimento e dividendo (forward) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | N/D |
- GlobeNewswire
NFL Running Back Tevin Coleman and Family Team Up with GBT to Share Playbook for Families Affected by Sickle Cell Disease
Parents of 4-year-old daughter with sickle cell disease kick off education campaign around World Sickle Cell Day and Father’s DaySOUTH SAN FRANCISCO, Calif., June 16, 2022 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced a new partnership with New York Jets running back Tevin Coleman and his wife, Akilah, whose 4-year-old daughter lives with sickle cell disease (SCD), with the goal of educating, inspiring, and raising awareness about SCD – especially among
- GlobeNewswire
New GBT Multinational Survey Shines a Needed Light on the Misunderstood Realities, Unseen Burden and Care Challenges of Sickle Cell Disease
Sickle Cell Health Awareness, Perspectives and Experiences (SHAPE) survey developed with international steering committee of medical experts and patient advocatesSOUTH SAN FRANCISCO, Calif., June 13, 2022 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced results from the Sickle Cell Health Awareness, Perspectives and Experiences (SHAPE) survey, a multinational survey on the burden of sickle cell disease (SCD) and unmet needs as reported by more than 1,300 pa
- GlobeNewswire
GBT Presents Positive New Real-World Evidence Data at EHA2022 Congress Further Supporting Clinical Use of Oxbryta® (voxelotor) in Sickle Cell Disease
Positive results from Phase 1 study of GBT601, including incremental new data, support advancing into planned Phase 2/3 trial by mid-year GBT to hold investor conference call and webcast today at 3:00 p.m. CEST (9:00 a.m. EDT) to highlight EHA data and provide business updates SOUTH SAN FRANCISCO, Calif., June 10, 2022 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced new data from a large multicenter real-world evidence study supporting the clinical use of
